Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis

Young Youn Cho, Minjong Lee, Hyo Cheol Kim, Jin Wook Chung, Yun Hwan Kim, Geum Youn Gwak, Si Hyun Bae, Do Young Kim, Jeong Heo, Yoon Jun Kim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

METHODS: We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients had PVT without extrahepatic metastasis and were treated with radioembolization in one of six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive PVT patients without extrahepatic metastasis from a single center who received sorafenib treatment to serve as the control group. We used inverse probability weighting (IPW) using propensity scores to adjust for the between-group differences in baseline characteristics.

BACKGROUND/AIMS: Limited treatment options are available for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 microspheres is a new treatment modality for HCC with PVT. For this analysis, we compared responses to treatment with radioembolization and with sorafenib.

RESULTS: At 3 months, the response rate and disease control rate were 32.1% (9/32) and 57.1% (16/32), respectively, in the radioembolization group and 3.2% (1/31) and 41.9% (13/31) in the sorafenib group. Median overall survival (OS) and time to progression (TTP) were not significantly different between the radioembolization group and the sorafenib group (13.8 months and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to balance the population characteristics. The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0.01).

CONCLUSION: HCC patients with PVT who underwent radioembolization achieved comparable survival to patients who received sorafenib, even after application of IPW. The radioembolization group also experienced fewer severe adverse effects. Radioembolization can be considered a new treatment option for patients with HCC with PVT.

Original languageEnglish
Pages (from-to)e0154986
JournalPLoS One
Volume11
Issue number5
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Propensity Score
portal vein
thrombosis
hepatoma
Portal Vein
Hepatocellular Carcinoma
Thrombosis
metastasis
Therapeutics
Survival
Disease control
Yttrium
adverse effects
yttrium
Neoplasm Metastasis
Microspheres
population characteristics
Population Characteristics
Korea
sorafenib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis : A Propensity Score Analysis. / Cho, Young Youn; Lee, Minjong; Kim, Hyo Cheol; Chung, Jin Wook; Kim, Yun Hwan; Gwak, Geum Youn; Bae, Si Hyun; Kim, Do Young; Heo, Jeong; Kim, Yoon Jun.

In: PLoS One, Vol. 11, No. 5, 01.01.2016, p. e0154986.

Research output: Contribution to journalArticle

Cho, Young Youn ; Lee, Minjong ; Kim, Hyo Cheol ; Chung, Jin Wook ; Kim, Yun Hwan ; Gwak, Geum Youn ; Bae, Si Hyun ; Kim, Do Young ; Heo, Jeong ; Kim, Yoon Jun. / Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis : A Propensity Score Analysis. In: PLoS One. 2016 ; Vol. 11, No. 5. pp. e0154986.
@article{13352c998c364c7db2e2a6d20fa73495,
title = "Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis",
abstract = "METHODS: We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients had PVT without extrahepatic metastasis and were treated with radioembolization in one of six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive PVT patients without extrahepatic metastasis from a single center who received sorafenib treatment to serve as the control group. We used inverse probability weighting (IPW) using propensity scores to adjust for the between-group differences in baseline characteristics.BACKGROUND/AIMS: Limited treatment options are available for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 microspheres is a new treatment modality for HCC with PVT. For this analysis, we compared responses to treatment with radioembolization and with sorafenib.RESULTS: At 3 months, the response rate and disease control rate were 32.1{\%} (9/32) and 57.1{\%} (16/32), respectively, in the radioembolization group and 3.2{\%} (1/31) and 41.9{\%} (13/31) in the sorafenib group. Median overall survival (OS) and time to progression (TTP) were not significantly different between the radioembolization group and the sorafenib group (13.8 months and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to balance the population characteristics. The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0.01).CONCLUSION: HCC patients with PVT who underwent radioembolization achieved comparable survival to patients who received sorafenib, even after application of IPW. The radioembolization group also experienced fewer severe adverse effects. Radioembolization can be considered a new treatment option for patients with HCC with PVT.",
author = "Cho, {Young Youn} and Minjong Lee and Kim, {Hyo Cheol} and Chung, {Jin Wook} and Kim, {Yun Hwan} and Gwak, {Geum Youn} and Bae, {Si Hyun} and Kim, {Do Young} and Jeong Heo and Kim, {Yoon Jun}",
year = "2016",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0154986",
language = "English",
volume = "11",
pages = "e0154986",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis

T2 - A Propensity Score Analysis

AU - Cho, Young Youn

AU - Lee, Minjong

AU - Kim, Hyo Cheol

AU - Chung, Jin Wook

AU - Kim, Yun Hwan

AU - Gwak, Geum Youn

AU - Bae, Si Hyun

AU - Kim, Do Young

AU - Heo, Jeong

AU - Kim, Yoon Jun

PY - 2016/1/1

Y1 - 2016/1/1

N2 - METHODS: We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients had PVT without extrahepatic metastasis and were treated with radioembolization in one of six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive PVT patients without extrahepatic metastasis from a single center who received sorafenib treatment to serve as the control group. We used inverse probability weighting (IPW) using propensity scores to adjust for the between-group differences in baseline characteristics.BACKGROUND/AIMS: Limited treatment options are available for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 microspheres is a new treatment modality for HCC with PVT. For this analysis, we compared responses to treatment with radioembolization and with sorafenib.RESULTS: At 3 months, the response rate and disease control rate were 32.1% (9/32) and 57.1% (16/32), respectively, in the radioembolization group and 3.2% (1/31) and 41.9% (13/31) in the sorafenib group. Median overall survival (OS) and time to progression (TTP) were not significantly different between the radioembolization group and the sorafenib group (13.8 months and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to balance the population characteristics. The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0.01).CONCLUSION: HCC patients with PVT who underwent radioembolization achieved comparable survival to patients who received sorafenib, even after application of IPW. The radioembolization group also experienced fewer severe adverse effects. Radioembolization can be considered a new treatment option for patients with HCC with PVT.

AB - METHODS: We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients had PVT without extrahepatic metastasis and were treated with radioembolization in one of six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive PVT patients without extrahepatic metastasis from a single center who received sorafenib treatment to serve as the control group. We used inverse probability weighting (IPW) using propensity scores to adjust for the between-group differences in baseline characteristics.BACKGROUND/AIMS: Limited treatment options are available for patients with hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 microspheres is a new treatment modality for HCC with PVT. For this analysis, we compared responses to treatment with radioembolization and with sorafenib.RESULTS: At 3 months, the response rate and disease control rate were 32.1% (9/32) and 57.1% (16/32), respectively, in the radioembolization group and 3.2% (1/31) and 41.9% (13/31) in the sorafenib group. Median overall survival (OS) and time to progression (TTP) were not significantly different between the radioembolization group and the sorafenib group (13.8 months and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to balance the population characteristics. The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0.01).CONCLUSION: HCC patients with PVT who underwent radioembolization achieved comparable survival to patients who received sorafenib, even after application of IPW. The radioembolization group also experienced fewer severe adverse effects. Radioembolization can be considered a new treatment option for patients with HCC with PVT.

UR - http://www.scopus.com/inward/record.url?scp=84991507560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991507560&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0154986

DO - 10.1371/journal.pone.0154986

M3 - Article

C2 - 27149067

AN - SCOPUS:84991507560

VL - 11

SP - e0154986

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

ER -